SCHEMBL936648

SCHEMBL936648

COC(=O)c1cc(Cn2cncn2)cc(NS(=O)(=O)c2ccc(OCc3ccccc3)c(F)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 3/20 0.43
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
CYP19A1 P11511 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
KAT6A Q92794 1/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 1/20 0.38
FABP4 P15090 1/20 0.38
HPGD P15428 1/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
HTT P42858 1/20 0.37
PPIA P62937 1/20 0.37
AR P10275 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12944797 0.88 WDR5 (0.43) MEN1KMT2ACYP19A1FABP4KDM4E
SCHEMBL935972 0.86 CYP19A1 (0.42) MEN1KMT2ACYP19A1ALDH1A1KDM4E
SCHEMBL935343 0.85 KDM4E (0.41) MEN1KMT2ACYP19A1HDAC1HDAC6
SCHEMBL13240265 0.83 KDM4E (0.36) MEN1KMT2ACYP19A1HDAC1HDAC6
SCHEMBL937743 0.75 NR1H4 (0.51) MEN1KMT2AHDAC1HDAC6LMNA
SCHEMBL935631 0.74 NPC1 (0.43) MEN1KMT2AHDAC1HDAC6LMNA
SCHEMBL936067 0.70 AR (0.63) MEN1KMT2ALMNAHPGDKDM4E
SCHEMBL12908853 0.70 CYP1A2 (0.39) MEN1KMT2AHDAC1HDAC6
SCHEMBL937045 0.69 HDAC1 (0.51) MEN1KMT2ACYP19A1HDAC1HDAC6
SCHEMBL306427 0.69 HDAC1 (0.70) CYP19A1HDAC1HDAC6HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470860-B2 Phenyl-sulfamates as aromatase inhibitors STERIX LIMITED (GB) 2013-06-25 US disclosed
US-8470860-B2 Phenyl-sulfamates as aromatase inhibitors STERIX LIMITED (GB) 2013-06-25 US disclosed
US-20110021586-A1 PHENYL-SULFAMATES AS AROMATASE INHIBITORS STERIX, LIMITED (GB) 2011-01-27 US disclosed
US-20110021586-A1 PHENYL-SULFAMATES AS AROMATASE INHIBITORS STERIX, LIMITED (GB) 2011-01-27 US disclosed
US-7763642-B2 Phenyl-sulfamates as aromatase inhibitors STERIX LTD. (GB) 2010-07-27 US disclosed
US-7763642-B2 Phenyl-sulfamates as aromatase inhibitors STERIX LTD. (GB) 2010-07-27 US disclosed
US-7763642-B2 Phenyl-sulfamates as aromatase inhibitors STERIX LTD. (GB) 2010-07-27 US disclosed
EP-1753732-B1 PHENYL-SULFAMATES AS AROMATASE INHIBITORS STERIX LTD (GB) 2009-12-02 EP disclosed
US-20070117855-A1 Phenyl-sulfamates as aromatase inhibitors STERIX LIMITED (GB) 2007-05-24 US disclosed
US-20070117855-A1 Phenyl-sulfamates as aromatase inhibitors STERIX LIMITED (GB) 2007-05-24 US disclosed
US-20070117855-A1 Phenyl-sulfamates as aromatase inhibitors STERIX LIMITED (GB) 2007-05-24 US disclosed
EP-1753732-A1 PHENYL-SULFAMATES AS AROMATASE INHIBITORS Sterix Limited (GB) 2007-02-21 EP disclosed
WO-2005118560-A1 PHENYL-SULFAMATES AS AROMATASE INHIBITORS STERIX LIMITED (GB) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117855-A1 Phenyl-sulfamates as aromatase inhibitors CYP19A1, CYP17A1, CYP21A2 SCN9A 2523/4885MEN1 3186/4885KMT2A 907/4885
US-20110021586-A1 PHENYL-SULFAMATES AS AROMATASE INHIBITORS CYP19A1, CYP17A1, CYP21A2 SCN9A 2523/4885MEN1 3186/4885KMT2A 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.